1. Home
  2. DSY vs RNTX Comparison

DSY vs RNTX Comparison

Compare DSY & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DSY

Big Tree Cloud Holdings Limited Ordinary Shares

HOLD

Current Price

$3.11

Market Cap

28.5M

Sector

N/A

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSY
RNTX
Founded
2020
2001
Country
China
United States
Employees
N/A
11
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.5M
30.0M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
DSY
RNTX
Price
$3.11
$1.17
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
105.9K
83.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$1.02
52 Week High
$4.01
$2.27

Technical Indicators

Market Signals
Indicator
DSY
RNTX
Relative Strength Index (RSI) 79.20 46.42
Support Level $0.33 $1.06
Resistance Level $4.01 $1.29
Average True Range (ATR) 0.19 0.10
MACD 0.26 0.01
Stochastic Oscillator 75.52 38.46

Price Performance

Historical Comparison
DSY
RNTX

About DSY Big Tree Cloud Holdings Limited Ordinary Shares

Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: